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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.018Duchenne muscular dystrophy (DMD) is a severe disorder characterized by progressive muscle wasting,
respiratory and cardiac impairments, and premature death. No treatment exists so far, and the iden-
tiﬁcation of active substances to ﬁght DMD is urgently needed. We found that tamoxifen, a drug used to
treat estrogen-dependent breast cancer, caused remarkable improvements of muscle force and of
diaphragm and cardiac structure in the mdx5Cv mouse model of DMD. Oral tamoxifen treatment from
3 weeks of age for 15 months at a dose of 10 mg/kg/day stabilized myoﬁber membranes, normalized
whole body force, and increased force production and resistance to repeated contractions of the triceps
muscle above normal values. Tamoxifen improved the structure of leg muscles and diminished cardiac
ﬁbrosis by w50%. Tamoxifen also reduced ﬁbrosis in the diaphragm, while increasing its thickness,
myoﬁber count, and myoﬁber diameter, thereby augmenting by 72% the amount of contractile tissue
available for respiratory function. Tamoxifen conferred a markedly slower phenotype to the muscles.
Tamoxifen and its metabolites were present in nanomolar concentrations in plasma and muscles,
suggesting signaling through high-afﬁnity targets. Interestingly, the estrogen receptors ERa and ERb
were several times more abundant in dystrophic than in normal muscles, and tamoxifen normalized the
relative abundance of ERb isoforms. Our ﬁndings suggest that tamoxifen might be a useful therapy for
DMD. (Am J Pathol 2013, 182: 485e504; http://dx.doi.org/10.1016/j.ajpath.2012.10.018)Supported by Swiss National Science Foundation grant 3100A0-109981
(U.T.R.), REQUIP grant 326000-121314/1 (L.A.D.), the Duchenne Parent
Project-The Netherlands (DPP-NL; S17474 DPP 2011-12), the Association
Française contre les Myopathies (AFM; 13090, 13984, and 15093), and
a Ph.D. student fellowship grant from the AFM (13091 to J.R.-P.).
Current address of O.M.D., Department of Cell Biology, University of
Geneva, Geneva, Switzerland; of S.A.C., Centre for High-Throughput
Biology, University of British Columbia, Vancouver, BC, Canada.Duchenne muscular dystrophy (DMD) is a common and
fatal genetic disease that affects the striated muscles in boys.
It is characterized by muscle wasting, starting at w3 years
of age, leading to progressive paralysis and loss of ambu-
lation during the teenage years and cardiac dysfunctions that
cause death in early adulthood.1
DMD results from the inability of muscles to express
dystrophin, a large subsarcolemmal protein that bridges
the extracellular matrix to the intracellular cytoskeleton.
Dystrophin is essential for protecting muscle cells from
contraction-induced mechanical damage and for regulating
processes in the subsarcolemmal space, such as mechano-
transduction, reactive oxygen species production, and cation
channel activity. The absence of dystrophin causes calcium
overload, oxidative stress, and impairment of mitochondrial
functions, which, collectively, alter myoﬁbrillar functionstigative Pathology.
.and cause muscle cell death.2,3 The ensuing chronic
inﬂammation impairs muscle regeneration and renders the
surviving ﬁbers more susceptible to stress. The dystrop-
hic muscles are progressively invaded by connective and
adipose tissues,1 resulting in a dramatic loss of muscle
strength. Disease progression to the respiratory muscles
[eg, the diaphragm (DIA)] and the heart greatly restricts the
life expectancy of patients with DMD.4,5
Dorchies et alSo far, the only pharmacologic treatments that have been
clinically validated for patients with DMD are the glucocorti-
coids, prednisolone, and deﬂazacort.6 However, these drugs
prolong muscle strength and ambulation of patients only for
a short term,6 and adverse effects lead somepatientswithDMD
to discontinue treatment. The identiﬁcation of additional
pharmacologic compounds that would decrease the course of
the disease remains a major goal for research.7,8
Estrogens have long been regarded as female sex hormones.
The expression of the estrogen receptors (ERs) ERa and ERb,
which mediate most estrogen actions, and aromatase, the rate-
limiting enzyme that produces estrogens from androgens, was
found in skeletal muscle.9e11 In fact, skeletal muscles are
major sites of estrogen production inmen and postmenopausal
women. Overall, estrogens increase force output,12 enhance
muscle recovery from disuse atrophy,13 protect skeletal
muscle membrane from contraction-induced injury,14 and
reduce the risk of developing cardiovascular diseases.15,16
Selective estrogen receptor modulators (SERMs) are com-
pounds that either mimic or antagonize estrogens in a tissue-
dependent manner. Tamoxifen (TAM), a ﬁrst-generation
SERM with antiestrogenic activity on the mammary gland,
has been used to prevent and treat breast cancers for>20 years.
At the same time, its proestrogenic activity on bone has made
it attractive for the treatment of osteoporosis.17e19 TAM has
shown efﬁcacy in scavenging peroxyl radicals,20 stabilizing
biological membranes,14 preventing apoptosis,21 inhibiting
ﬁbrosis,22,23 and modulating calcium homeostasis.24e26
Because these features all contribute to the pathogenesis of
DMD, we hypothesized that dystrophic muscles could beneﬁt
from chronic TAM treatment.
We found that oral administration of TAM at a dose of 10
mg/kg/day for 15 months to mdx5Cv mice, a commonly used
model for DMD, remarkably improved dystrophic muscle
structure and function. Speciﬁcally, TAM improved the
whole body force of living mice, increased the force of leg
muscles above that of normal mice, rendered these muscles
more resistant to fatigue, induced a shift toward a slower
phenotype, stabilized muscle ﬁber membrane, and norm-
alized their diameter. Importantly, TAM decreased the
development of ﬁbrotic tissue in the DIA and in the heart and
considerably increased the amount of contractile muscle
tissue in the DIA. All these effects were obtained with plasma
and muscle concentrations of TAM and its active metabolites
being in the low nanomolar range, well below the levels
displayed by patients with breast cancer under standard TAM
therapy (ie, 20 mg/day). ERa and ERb proteins were both
overexpressed several fold in dystrophic muscles, and TAM
altered the relative abundance of the ERb isoforms ERb1 and
ERb2 at both the mRNA and at the protein levels. Because
ERb2 may function as an inhibitor of ERb1 and the ERb2-to-
ERb1 ratio partly controls ER signaling,27,28 these alterations
of ER levels are likely signiﬁcant in the exceptional
responsiveness of dystrophic muscles to TAM.
Because TAM has a good safety proﬁle, not only in
adults but also in children, our ﬁndings suggest that486TAM might be helpful for the treatment of patients with
DMD.
Materials and Methods
While this study was ongoing, we contributed to the elab-
oration of standard operating procedures for preclinical
investigations in the dystrophic mouse.29 Whenever pos-
sible, the present study was performed in accordance with
the experts’ recommendations.
Mice and Treatments
All procedures involving animals complied with the Swiss
Federal Law on Animal Welfare. Colonies of dystrophic
mdx5Cv mice30 (The Jackson Laboratory, Bar Harbor, ME),
and wild-type (wt) C57BL/6J mice (Charles River France,
Saint Germain sur l’Arbresle, France) were maintained at
the School of Pharmaceutical Sciences. Mice were housed
in plastic cages containing wood granule bedding, kept on
a 12-hour dark/12-hour light cycle, and allowed unlimited
access to food and water.
Tamoxifen [(Z)-tamoxifen, catalog numberT-5648; Sigma-
Aldrich, Buchs, Switzerland] was incorporated into standard
rodent diet at 100 mg/kg (Provimi-Kliba, Kaiseraugst,
Switzerland). Both control and TAM-containing pellets were
stored at 20C in 0.5-kg vacuum-sealed bags. Male pups
were marked by microtattooing of the toes under slight
ketamine-xylazine sedation. Three groups were treated for
approximately 15 months (63 1 week) starting on postnatal
day 21, that is, at the time when necrosis starts in most leg
muscles: 14 dystrophic males were given control diet (Dys
group), 12 dystrophic males were given TAM-containing diet
(TAM group), and 12 wt males were given control diet (wt
group). Body weights and food consumption were monitored
weekly. A group of 9 dystrophic females fed control diet
(FEM group) was included for comparison of certain end
points with the groups of male mice.
Wire Grip Test
After 58 to 60 weeks of treatment, a wire test was used to
assess whole body force. The mice were allowed to grasp by
their four paws a 2-mm diameter metal wire maintained hori-
zontally 35 cm above a thick layer of soft bedding. The length
of time until the mice fell from the wire was recorded. After
each fall, the mice were allowed to recover for 1 minute. Each
session consisted of three trials from which the scores were
averaged. The ﬁnal grid test score was calculated as the av-
erage value from three sessions performed at 1-week intervals.
Muscle Contraction Properties
At the end of the treatment period, mice were anesthetized,
and muscle responses to electrical stimulations were recor-
ded isometrically in the right triceps surae as previouslyajp.amjpathol.org - The American Journal of Pathology
Tamoxifen Ameliorates Muscular Dystrophydescribed.31e36 At the end of the treatment period, mice
were anesthetized by an i.p. injection of a mixture of ure-
thane (1.5 g/kg) and diazepam (5 mg/kg). In brief, the knee
joint was ﬁrmly immobilized, and the Achilles tendon was
linked to a force transducer coupled to a LabView interface
(National Instruments, Austin, TX). Two thin steel elec-
trodes were inserted intramuscularly, and 0.5-ms pulses of
controlled intensity and frequency were delivered. After
manual settings of optimal muscle length (Lo) and optimal
current intensity, ﬁve phasic twitches were recorded at
a sampling rate of 3 kHz to determine the absolute peak
twitch force (Pt), the time to peak twitch tension (TTP), the
time for half relaxation from peak twitch tension (RT1/2),
the maximum rate of tension development (Tdev), and the
maximum rate of tension loss (Tloss). After a 3-minute
pause, muscles were subjected to a force-frequency test:
200-ms long stimuli of increasing frequencies (10 to 100 Hz
by increments of 10 Hz) were delivered at intervals of 30
seconds. When necessary, further stimulations at 120, 150,
and 200 Hz were delivered to obtain the maximum
response, which was taken as the absolute optimal tetanic
tension (Po). After another 3-minute pause, the resistance of
the triceps to repeated tetani was assayed. Frequency was set
at 60 Hz, and muscle tension was recorded while
stimulations were repeatedly delivered, each consisting of
a 1-second burst and a 3-second rest. The responses were
expressed as the percentage of the maximal tension. Absolute
phasic and tetanic tensions were converted into speciﬁc
tensions (in mN per mm2 of muscle section) after normali-
zation for themuscle cross-sectional area. The cross-sectional
area values (in mm2) were determined by dividing the triceps
surae muscle mass (in mg) by the product of the optimal
muscle length (in mm) and the density of mammalian skeletal
muscle (1.06 mg/mm3).
Tissue Collection and Plasma CK
Immediately after isometric force recording, heparin was
injected into the heart (30 mL, 3000 IU/mL), the mice were
bled, and plasma was prepared by centrifugation (1000 x g,
10 minutes, 4C). Skeletal muscles and other selected org-
ans were dissected and weighed. Plasma creatine kinase
(CK) levels were determined with a commercial kit (Cata-
chem; Investcare Vet, Middlesex, UK) according to the
manufacturer’s recommendations.
Quantiﬁcation of TAM and of Its Metabolites
The concentrations of the TAM isomers (E)-TAM and
(Z)-TAM, and the TAMmetabolites (E)-4-hydroxytamoxifen
(OH-TAM), (Z)-4-OH-TAM, (E)-N-desmethyl-TAM,
(Z)-N-desmethyl-TAM, (E)-4-hydroxy-N-desmethyl-TAM,
(Z)-4-hydroxy-N-desmethyl-TAM (endoxifen), in the plasma
of the TAM-treated mice were determined by an ultra perfor-
mance liquid chromatographyetandem mass spectrometry
assay as described.37 The levels of these compounds were alsoThe American Journal of Pathology - ajp.amjpathol.orgdetermined in the gastrocnemius (GAS) muscles from TAM-
treated mice with the use of a modiﬁcation of the method
used for plasma. Brieﬂy, the GAS muscles were pulverized in
liquid nitrogen-cooled mortars. Twenty milligrams of the
muscle powder was homogenized for 30 seconds with a tissue
tearor (Omni International, Kennesaw, GA) in a mixture
composed of 900 mL of absolute ethanol and 100 mL of
deuterated internal standards solution (25 ng/mL TAM-d5,
N-desmethyl-TAM-d5, 4-OH-TAM-d5, and 50 ng/mL
endoxifen-d5, 1:1 E/Z mixture, in methanol). The tissue
suspension was then centrifuged (4C for 10 minutes at
16000  g). Seven hundred microliters of the supernatant
ﬂuid was transferred into a propylene tube and dried under
nitrogen at room temperature. The residue was reconstituted
in 100 mL of acetonitrile, vortex-mixed, diluted with 200 mL
of a buffer solution (10 mmol/L ammonium formate, con-
taining 0.25% formic acid) and centrifuged again as above.
Supernatant ﬂuid (150 mL) was introduced in a high perfor-
mance liquid chromatography glass microvial, and 20 mLwas
injected into the high performance liquid chromatography
system. Ultra performance liquid chromatographyetandem
mass spectrometry conditions (mobile phases, elution
gradient, and mass spectrometer conditions) were identical to
those described for plasma levels measurements.37 Calibra-
tion curves for tissue samples, prepared in ethanolic matrix
(20 mg tissue/mL), ranged from 0.05 to 3 ng/mL for (E)-
endoxifen, 0.025 to 3 ng/mL for (Z)-endoxifen, and 0.013 to 3
ng/mL for (Z)-4-OH-TAM, (Z)-N-desmethyl-TAM, and (Z)-
TAM. In this speciﬁc setting, the method was precise and
accurate with the interassay precision (CV %) and accuracy
(bias %) ranging between 1% and 13% and8.9% and 6.1%,
respectively.
For plasma and muscle sample, (E)-TAM, (E)-N-
desmethyl-TAM, and (E)-4-OH-TAM levels were quan-
tiﬁed with the calibration curves of their corresponding Z
isomers. In plasma and tissue samples, E-TAM isomer
was chromatographically identiﬁed by comparison of its
retention time with that of the purchased pure standard
(Toronto Research Chemicals Inc., North York, ON,
Canada). (E)-N-desmethyl-TAM and (E)-4-OH-TAM iso-
mers were tentatively identiﬁed by comparison of their
retention times with those of E isomers produced in vitro
by exposing methanolic solutions of the corresponding Z
isomers to UV light (254 nm) for w3 hours.
The results are expressed as ng/mL of plasma, ng/g of
tissue, and nmol/L. A qualitative analysis of the food pellets
conﬁrmed that (Z)-TAM was the only form of TAM in the
TAM-containing diet and that the control diet was devoid of
TAM and metabolites.
Histologic Examination of Skeletal Muscles and
Morphometry
The extensor digitorum longus (EDL), GAS, soleus, and
tibialis anterior (TA) muscles from the right leg and the right
hemi-DIA were embedded in tragacanth gum, frozen in487
Dorchies et alliquid nitrogen-cooled isopentane, and stored at 80C until
processed further. Transverse sections 10 mm thick were
stained with H&E according to standard procedures, and
images covering the entire muscle sections were acquired
either with a Spot Insight camera (Visitron Systems, Puch-
heim, Germany) mounted on an Axiovert 200M microscope
(Zeiss, Feldbach, Switzerland) or with an Axiocam camera
(Zeiss) ﬁtted on a Mirax Midi automated microscope
(Zeiss), at a ﬁnal magniﬁcation of 50 or 200, respec-
tively. In dystrophic mice, skeletal muscles undergo re-
peated cycles of necrosis and regeneration with progressive
accumulation of adipose and connective tissues. In normal
ﬁbers, the nuclei are located close to the sarcolemma
(“peripheral nuclei”), whereas in regenerated ﬁbers the
nuclei remain internalized. On the basis of these morpho-
logic features, both normal and regenerated ﬁbers were
counted. Regenerated ﬁbers are expressed as the percentage
of the total muscle ﬁbers.
Sections were incubated with 2 mg/mL wheat germ
agglutinin conjugated to Alexa Fluor 488 (WGA-AF488;
Molecular Probes, Invitrogen, Basel, Switzerland) in
phosphate-buffered saline for 1 hour at room temperature to
stain the connective tissue as described.36 Fluorescence
images from the whole muscle surface were taken with
a Mirax Midi microscope as described above. The area
covered by the connective tissue was measured with the
Metamorph software version 5.0r7 (Visitron Systems,
Puchheim, Germany) and expressed as the percentage of the
total muscle area. In addition, the minimum ﬁber diameter
was determined in the GAS, DIA, EDL, TA, and soleus
muscles with the use of the Metamorph software as
described.38 For each muscle >500 ﬁbers were counted
from four to six ﬁelds taken at a ﬁnal magniﬁcation of200.
Fiber typing was performed by immunohistochemistry
with the use of mouse monoclonal antibodies against speciﬁc
myosin heavy chains (MyHCs), according to standard
procedures. The primary monoclonal antibodies BA-D5, SC-
71, BF-35, and BF-F3 (Developmental Studies Hybridoma
Bank, Iowa City, IA) were used to reveal ﬁbers expressing
type I, type IIA, all types but IIX, and type IIB MyHCs,
respectively. The BA-D5, SC-71, and BF-35 antibodies were
detected with a goat anti-mouse IgG antibody conjugated to
Alexa Fluor 594 (Molecular Probes), and the connective
tissue was counterstained with WGA-AF488 as described
above. The BF-F3 antibody was detected with a goat anti-
mouse IgM antibody conjugated to Alexa Fluor 488
(Molecular Probes). Fibers of type I and of type IIA were
counted on separate sections. Other sections were double-
stained with the anti-type IIB and all anti-types but IIX as
above, and the connective tissue was counterstained with
WGA-AF594 (Molecular Probes). The negative ﬁbers were
classiﬁed as IIX, and the yellow ﬁbers (resulting from the
superimposition of the green and red staining) were classi-
ﬁed as IIB. The number of ﬁbers expressing a given MyHC
was determined with ImageJ version 1.46r (NIH, Bethesda,
MD) from the whole TA, EDL, and soleus muscles, from the488right hemi-DIA, and from the lateral GAS muscle and was
expressed as the percentage of the total ﬁber count.
Further morphometric analyses were performed on the
right hemi-DIA after H&E staining as follows. Approxi-
mately 10 images at a ﬁnal magniﬁcation of 100 were
needed to capture the whole surface. Each image was viewed
with ImageJ software, and lines were drawn at three preset
locations equally distributed perpendicularly to the long axis
of the DIA. At these locations, the thickness of the DIA was
measured, and the number of myoﬁbers crossing these lines
was counted. The adipose tissue was identiﬁed as unstained
“empty” ﬁbers demarcated by perimysial connective struc-
tures. The foci of adipose tissue were demarcated with
Photoshop software version 7.0 (Adobe, San Jose, CA).
Then, the corresponding areas were quantiﬁed with ImageJ
software and expressed as the percentage of the total muscle
area. An approximate value of the area occupied by muscle
cells (both normal and regenerated ﬁbers) in the DIA
was obtained by subtracting the surfaces of adipose and
connective tissues from the total muscle surface.
Determination of Cardiac Fibrosis
Hearts were ﬁxed in 4% buffered paraformaldehyde. After
inclusion in parafﬁn, 5-mm-thick sections across the ven-
tricles were collected 1.50 mm, 2.25 mm, and 3.00 mm from
the apex and stained with Masson trichrome. The entire
cross-sections were microphotographed with a Mirax Midi
microscope at a ﬁnal magniﬁcation of 200. Each virtually
reconstructed section was divided into four images from
which the area covered by ﬁbrotic deposits (appearing as
a blue staining on a red background) was quantiﬁed with
ImageJ software and expressed as the percentage of the total
tissue surface. Finally, the values obtained from the three
sections were averaged.
ER mRNA Expression
The left GAS muscle was snap-frozen in liquid nitrogen
and stored at80C until processed. Themuscles were ground
to aﬁne powder inmortars cooled in liquid nitrogen.RNAwere
extracted from 10 mg of muscle powder (RNeasy Fibrous
Tissue mini kit; Qiagen, Hombrechtikon, Switzerland), and
100 ng of total RNA was reverse-transcribed with Super-
Script II Reverse Transcriptase (Invitrogen). The cDNA
corresponding to 1 ng of reverse-transcribed total RNA was
subjected to quantitative PCR (qPCR) ampliﬁcation with the
use of SYBR detection. To quantify the overall ERa or ERb
variants, primers were designed in regions that are not
affected by alternative splicing. The expression levels of ERa
and ERb relative to the levels in the Dys group were deter-
mined with the TATA box-binding protein (TBP) as the
invariant housekeeping gene.
The identiﬁcation of the ERb mRNA variants encoding
the ERb1, ERb2, ERb5, ERb5A, and ERb6 isoforms (as
deﬁned under the Accession number O08537 of theajp.amjpathol.org - The American Journal of Pathology
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performed by PCR as described.39 Brieﬂy, 1 mL of GAS
muscle cDNA was subjected to PCR ampliﬁcation with the
use of primers annealing to exons 5 and 10 and under the
following conditions: 95C for 60 seconds; 40 cycles con-
sisting of 95C for 20 seconds, 55C for 30 seconds, and
72C for 60 seconds; and a ﬁnal elongation step at 72C for
5 minutes. As positive controls, mRNA from ovaries and
brain were run in parallel. Three microliters (GAS muscle)
or 0.1 mL (ovary) of the PCR product was resolved on
denaturing polyacrylamide-urea gels (5W, 2 hours, 57C) as
described.39 After silver staining, the gels were air-dried
between two sheets of cellophane and scanned, and densi-
tometric analysis of the signals was performed with ImageJ
software. Alternatively, 1000-fold dilutions of the PCR
products were used as templates for a second round of PCR
ampliﬁcation with the use of primers hybridizing to exons 6
and 8. The conditions were as described above, except that
35 cycles were performed and the annealing temperature
was set to 60C. Ten microliters (GAS muscle), 3 mL
(brain), or 0.3 mL (ovary) of the second PCR products were
resolved on 1.2% agarose gels and stained with ethidium
bromide before quantiﬁcation of ERb1 and ERb2 signals.
The primers used are shown inTable 1. Theywere designed
from the sequences published under the NCBI Accession
numbers NM_007956.4 (mouse ERa), NM_010157.3
(mouse ERb1), NM_207707.1 (mouse ERb2), and
NM_013684.3 (mouse TATA box-binding protein).
Protein Expression
Muscle extracts were prepared from the left GAS muscle
powder as described.34 The ﬁnal protein concentration was
adjusted to 3 mg/mL with reducing Laemmli buffer. Muscle
extracts (30 to 60 mg/lane) were resolved by SDS-PAGE, and
proteins were transferred onto nitrocellulose membranes
according to standard procedures. Equal loading and transfer
efﬁciency were veriﬁed by staining with Ponceau Red.
Membranes were blocked for 1 hour in TBST (20 mmol/L
Tris-base, 150 mmol/L NaCl, 0.1% Tween-20, pH 7.5)Table 1 Primers used for analysis of estrogen receptor mRNA levels
Primer Exon Se
Primers used for determination of ER levels by RT-qPCR
ERa-forward 5 5
ERa-reverse 6 5
ERb-forward 2 5
ERb-reverse 3 5
TBP-forward 6 5
TBP-reverse 7 5
Primers used for determination of ER levels by RT-qPCR
ERb-forward 5 5
ERb-reverse 10 5
ERb-forward 6 5
ERb-reverse 8 5
*Amplicons corresponding to ERb2, ERb1, ERb6, ERb5, and ERb5A isoforms, res
yAmplicons corresponding to ERb2 and ERb1 isoforms, respectively.
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4C with a primary antibody (see Table 2 for detailed
information on the primary antibodies used, providers,
clonality, working dilutions, and nature of the competing
protein). After extensive washing, membranes were incu-
bated for 1 hour with an appropriate horseradish peroxidase-
conjugated secondary antibody in TBST containing 5%milk.
The bound antibody against ERb227 was detected with
protein Gehorseradish peroxidase in TBST-milk. Proteins
were revealed by chemiluminescence (ECL plus kit; Amer-
sham, GE Healthcare Europe, Glattbrugg, Switzerland) after
exposure to Fuji X-ray ﬁlms (Fujiﬁlm Europe, Dusseldorf,
Germany). The ﬁlms were scanned, and densitometric
analysis was performed with ImageJ software. Signals were
normalized to the MyHC content (determined on separate
gels stained with Coomassie Blue) and corrected for the
intensity of a reference sample loaded several times on every
gel for the purpose of intragel and intergel comparisons.34
Data and Statistical Analysis
One wt mouse and one Dys mouse died at 55 and 64 weeks
of age, respectively. Two Dys mice, one TAM mouse, and
one FEM mouse died on preterminal anesthesia. Thus, the
data presented here were collected from 11 to 14 males and
from 8 to 9 females and expressed as the means  SEMs.
GraphPad Prism software version 5.03 (GraphPad, San
Diego, CA) was used for constructing the graphs and for
performing the statistical analyses. The differences between
groups were assessed by one-way analysis of variance fol-
lowed by Tukey’s multiple comparison posttest. Differences
with P values  0.05 were considered signiﬁcant.
Results
Effects of TAM Treatment on Mouse Behavior, Body
Weight, and Food Intake
The mice did not show noticeable alterations of their
behavior during the 15 months of TAM treatment. Overall,quence Amplicon size (bp)
0-TGCGCAAGTGTTACGAAGTG-30
0-TTTCGGCCTTCCAAGTCATC-30 109
0-TCGCTTCTCTATGCAGAACC-30
0-AGAAGTGAGCATCCCTCTTG-30 138
0-TGCTGCAGTCATCATGAG-30
0-CTTGCTGCTAGTCTGGATTG-30 115
0-TGAAGGAGCTACTGCTGAAC-30
0-CCCACTTCTGACCATCATTG-30 914, 860, 726, 721, 587*
0-GCTGATGGTGGGGCTGATGT-30
0-ATGCCAAAGATTTCCAGAAT-30 177, 123y
pectively.
489
Table 2 Characteristics of the antibodies used for analysis of protein levels
Antigen Host Clonality Clone Dilution Competitor Company Catalog no.
a7 Integrin* Rat M Cy8 1:2000 BSA NA NA
aB-crystallin Rabbit P NA 1:1000 BSA Calbiochem 238702
Calcineurin Rabbit P NA 1:1000 BSA Cell Signaling Technology 2614
Calsequestrin 1 Mouse M VIIID12 1:3000 BSA Thermo Scientific MA3-913
Calsequestrin 2 Rabbit P NA 1:2000 BSA Thermo Scientific PA1-913
ERa Rabbit P NA 1:400 Milk Santa Cruz Biotechnology sc-7207
ERb1 Rabbit P NA 1:1000 BSA Cell Signaling Technology 5513
ERb2 Rabbit P Twober.1y 1:1000 BSA NA NA
Parvalbumin Mouse M NA 1:2000 BSA Millipore MAB1572
SERCA1 Mouse M IIH11 1:2000 BSA Thermo Scientific MA3-911
SERCA2 Rabbit P NA 1:1000 BSA Abcam ab3625
Utrophin Mouse M DRP3/20C5 1:1000 Milk Novocastra NCL-DRP2
*Kindly donated by Prof. Randall H. Kramer (University of California, San Francisco, CA).
yDescribed previously.27
BSA, bovine serum albumin; M, monoclonal; NA, not applicable; P, polyclonal.
Dorchies et althe groups of untreated Dys males and of untreated wt males
showed similar growth curves (Supplemental Figure S1A).
The mice treated with TAM for 15 months (TAM) were
signiﬁcantly smaller throughout the study and, at sacriﬁce
they weighed the same as the untreated dystrophic females
(FEM; Supplemental Figure S1, A and B). From the food
consumption curves (Supplemental Figure S1C), we calcu-
lated that TAM intake decreased from 14 to 10 mg/kg/day
during the ﬁrst 17 weeks of treatment and then remained
at w10 mg/kg/day until the end of the study.
Effects of TAM Treatment on the Weight of Organs and
Muscles
The Dys mice had larger livers and testes than the wt mice.
TAM treatment fully normalized the relative weights ofTable 3 Effect of TAM treatment on the mechanical properties of the
Dys TAM
Phasic and tetanic isometric tensions
Pt, actual (mN) 902.0  39.2 100
Pt, speciﬁc (mN/mm
2) 81.9  2.9 16
Po, actual (mN) 3013  160 2
Po, speciﬁc (mN/mm
2) 273.9  11.3 46
Kinetics of contraction and relaxation
TTP (ms) 14.9  0.3 2
RT1/2 (ms) 15.9  0.5 2
Tdev (%max/ms) 14.75  0.50 9
Tloss (%max/ms) 4.09  0.25 2
Structural characteristics of the triceps surae
Mass, actual (mg) 190.2  3.4 11
Mass, corrected (mg/g) 5.26  0.11 4
Lo (mm) 16.40  0.19 17
CSA (mm2) 10.95  0.22 6
Data represent means  SEMs from 8 to 11 mice.
*P  0.05, **P  0.01, and ***P  0.001 compared with the Dys group.
yP  0.05, yyP  0.01, and yyyP  0.001 compared with the TAM group.
CSA, cross-sectional area; Lo, optimal muscle length; Po, optimal tetanic tensio
TTP, time to peak twitch tension.
490these organs (Supplemental Table S1). The mice in the
TAM group had signiﬁcantly less white fat and more brown
fat than the untreated Dys mice (Supplemental Table S1).
TAM treatment did not change the relative weights of the
other organs examined, such as the heart and the kidneys.
The Dys mice exhibited a signiﬁcant hypertrophy of all of
the skeletal muscles examined (Supplemental Table S1),
which is a common feature of the dystrophic mouse models.
Hypertrophy of the GAS, plantaris, soleus, and TA muscles
was partly rescued by TAM. The relative weight of the
triceps surae was completely normalized (Table 3). Overall,
TAM diminished the relative weights of the muscles close
to those of FEM mice, which showed less hypertrophy than
the Dys group. In marked contrast, TAM increased the
weight of the EDL muscle and the DIA. The relative
weights of the heart were similar in all groups.triceps muscle
wt FEM
1.5  127.2 1192.8  35.7** 516.6  19.0***yyy
2.3  16.6*** 109.9  3.3*y 66.1  2.4yyy
835  85 4573  197***yyy 2108  66***yyy
5.4  9.3*** 421.0  16.8***y 269.3  6.7yyy
3.2  1.5*** 16.4  0.3*yyy 15.1  0.6yyy
7.3  1.1*** 16.9  0.4yyy 18.1  1.2yyy
.42  0.77*** 15.28  0.31yyy 13.83  0.68yyy
.53  0.16*** 4.15  0.18yyy 3.37  0.26y
2.1  4.3*** 189.0  3.8yyy 131.7  3.6***y
.43  0.12*** 4.70  0.09*** 4.47  0.11***
.28  0.20** 16.41  0.20yy 15.86  0.17yyy
.12  0.20*** 10.87  0.19yyy 7.84  0.21***
n; Pt, peak twitch tension; Tdev, tension development; Tloss, tension loss;
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Tamoxifen Ameliorates Muscular DystrophyEffect of TAM Treatment on the Wire Test Performance
Within the last weeks of the treatment period, a wire test
was used to assess whole body force. Typically, soon after
the mice were allowed to grasp the horizontal wire, they
started to move along the wire and tried to ﬂip around
their body’s axis to explore the wire in the other direction
(Figure 1A). The Dys animals rapidly lost the grip of their
hind paws, causing them to hang onto the wire with their
fore limbs only. From this position, the mice were rarely
able to bring their hind paws back onto the wire and were
unable to sustain their own body weight for more than a few
seconds at each testing (Figure 1A). By contrast, both the wt
and the TAM mice were able to move their fore limbs and
chest into an extended position over the wire, to bring their
hind limbs back onto the wire, and to turn around their
body’s axis to ﬂip from one direction of the wire toward the
other. The TAM group performed much better than the Dys
group and equally well as the wt group (Figure 1B). The
FEM group performed signiﬁcantly better than the Dys
group but remained signiﬁcantly weaker than the TAM
group. Given that the smaller body weight of the dystrophic
females and TAM-treated males could increase their score at
the wire test, we also expressed the physical impulse as the
product of the wire test score (in seconds) and the mouse
body weight (in g).40 The improved performance of the
TAM group compared with the Dys group was still marked,
whereas the FEM group performed as poorly as the Dys
group (Figure 1C).
Effect of TAM Treatment on Plasma CK Activity
Plasma CK activity was approximately three times higher
in dystrophic males than in normal males, revealing anFigure 1 Effect of TAM treatment on the wire test score. A wire test was used
mice treated with 10 mg/kg per day of tamoxifen for 15 months (TAM), male wild-t
mouse during the wire test. The mice were allowed to grasp a metal wire maintain
lost grip of their hind paws and hung onto the wire with their forelimbs only. From
than a few seconds before falling. B: The length of time until the mice fell from
dystrophic mice to maintain their grip. C: The physical impulse was calculated to t
TAM-treated males. The values represent means  SEMs of 9 to 14 mice. *P  0.05
0.01 compared with the TAM group.
The American Journal of Pathology - ajp.amjpathol.orgincreased fragility of dystrophic muscle membrane
(Figure 2). CK levels were much lower in dystrophic
females than in dystrophic males, suggesting a role for
estrogens in stabilizing muscle membranes. TAM treatment
reduced plasma CK levels to values not signiﬁcantly
different from those of normal males and of dystrophic
females (Figure 2).
Effects of TAM Treatment on Muscle Contractile
Properties
The isometric contractile characteristics of the triceps surae
muscle were determined at the end of the treatment period.
The muscle mechanics data are summarized in Table 3 and
the most remarkable ﬁndings are shown in Figure 3. After
correction for the body weight, the dystrophic triceps pre-
sented a slight hypertrophy compared with wt triceps. This
was normalized by TAM (Table 3). Both phasic tension (Pt)
and tetanic tension (Po) were reduced in dystrophic mice
compared with normal mice. Although the actual size of the
triceps of the TAM group was reduced compared with the
Dys group, the Pt and Po outputs were similar in both groups
(Table 3). Correction for the muscle cross-sectional area
showed that the Pt and Po developed by the TAM-treated
mice were considerably higher than those of the untreated
Dys mice (Figure 3, A and C). In fact, TAM treatment for
15 months increased the speciﬁc Pt and Po of the dystrophic
triceps by 100% and 70%, respectively. Remarkably, the
triceps of TAM-treated mice became signiﬁcantly stronger
per surface unit than those of normal mice (Table 3 and
Figure 3, A and C).
The time required to achieve maximum contraction (TTP)
was slightly longer in the wt group than in the Dys group,
whereas the time for RT1/2 was similar in both groupsto assess whole body force of male dystrophic mice (Dys), male dystrophic
ype mice (wt), and female dystrophic mice (FEM). A: Different views of a Dys
ed horizontally above a thick layer of soft bedding. The Dys animals rapidly
this position, they were unable to sustain their own body weight for more
the wire was recorded and showed that TAM normalized the ability of the
ake into account the smaller body weight of the dystrophic females and the
, **P  0.01, ***P  0.001 compared with the Dys group; yP  0.05, yyP 
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Figure 2 Effect of TAM treatment on plasma CK levels. Blood was
collected from male dystrophic mice (Dys), male dystrophic mice treated
with 10 mg/kg per day of tamoxifen for 15 months (TAM), male wild-type
mice (wt), and female dystrophic mice (FEM). The plasma was prepared by
centrifugation, and plasma CK levels were determined spectro-
photometrically with the use of a commercial kit. The values represent
means SEMs of 8 to 11 mice. ***P  0.001 compared with the Dys group.
Dorchies et al(Table 3 and Figure 3B). TAM treatment for 15 months
conferred the triceps surae a much slower phenotype.
Compared with the Dys group, the TTP value increas-
ed by 56% and the RT1/2 value by 72% (Table 3 and
Figure 3B). Accordingly, the rates of maximum tension
development during contraction or of maximum tension loss
during relaxation were 36% and 38% smaller, respectively
(Table 3). Consistent with the slower contraction, the TAM
group exhibited a marked leftward shift of the curve con-
necting the tension output to the frequency of stimulation
(Figure 3D).
We next evaluated the resistance of the triceps surae
against repeated tetanic contractions (Figure 3E). Previous
studies from our laboratory suggested that this drastic assay
showed the nonrecoverable fragility of the muscle toward
damaging contractions rather than fatigue resulting, for
instance, from limitation in oxygen supply or changes in the
redox balance.31 The tricep muscles of the Dys group
showed a sharp loss of force as the tetani were repeatedly
delivered. The normal mice were signiﬁcantly more resistant
during the ﬁrst 15 tetani, until their force dropped and
became similarly low as in the Dys group (Figure 3E). The
dystrophic females exhibited increased resistance compared
with the dystrophic males. TAM treatment for 15 months
caused the triceps to lose force at a lower rate than in the
untreated Dys group (Figure 3E). After a few tetani, the
resistance of the TAM group to contraction-induced loss of
force showed a signiﬁcant improvement compared with the
Dys group. Of note, the muscle resistance of the TAM
group closely paralleled that of the FEM group (Figure 3E).
The force drop index was calculated as the average differ-
ence between the experimental values and the response492elicited by the ﬁrst tetanus. The loss of force in the TAM
and FEM groups was signiﬁcantly less than that of the Dys
and wt groups (Figure 3F).
Effects of TAM Treatment on Leg Muscle Structure
Examination of sections of EDL, soleus, and TA muscles
stained with H&E or wheat-germ agglutinin showed in the
Dys group well-known dystrophic changes, such as ﬁbers
with centrally located nuclei, indicative of muscle ﬁber
regeneration, and excessive connective tissue. Exhaustive
morphometric analyses showed that TAM caused diverse
effects on different muscles with respect to centronucleated
ﬁbers, ﬁbrosis, number of myoﬁbers, and myoﬁber size
(Supplemental Figures S2 and S3).
Effects of TAM Treatment on Diaphragm Morphology
H&E and wheat germ agglutinin staining revealed that
long-term TAM treatment improved the quality of the DIA
(Figure 4A and B, and Supplemental Figure S2, JeL).
Fibrosis was signiﬁcantly reduced (21%) by TAM treat-
ment (Figure 4, B and C). Interestingly, DIA from TAM-
treated Dys mice were signiﬁcantly heavier (76%) and
thicker (59%) than those of untreated Dys mice (Figure 4, D
and E). Further analysis demonstrated that these DIAs pre-
sented a signiﬁcantly higher number of ﬁbers (67%) and
more ﬁber layers (48%) (Figure 4, FeH). The number of
centronucleated ﬁbers was signiﬁcantly increased (33%),
suggesting that more regeneration occurred (Figure 4I). In
addition, the mean ﬁber diameter was increased close to that
of the wt mice (Figure 4J), and the fraction of muscle cells
to the total muscle surface was increased (21%) (Figure 4C).
When combining the increased thickness of the DIA with
the increased surface occupied by the myoﬁbers, TAM
augmented the amount of contractile tissue in the DIA
by 72%.
Effect of TAM Treatment on Heart Fibrosis
Fibrosis was w3.5 times higher in Dys hearts than in the
wt hearts (3.04% and 0.87% of the heart cross-sections,
respectively) (Figure 5, AeC). Cardiac ﬁbrosis was similar
in the FEM group and in the Dys group. After TAM treat-
ment, ﬁbrosis was reduced to 1.86% of the ventricular
surface, showing that TAM prevented the development of
ﬁbrosis in dystrophic hearts by w53% (Figure 5C).
Effects of TAM Treatment on Fiber Type Distribution
Fiber typing was performed with ﬂuorescent antibodies di-
rected against speciﬁc MyHC isoforms. We found subtle
differences in the distribution of MyHCs between the
Dys and wt groups (Supplemental Figure S4, AeE). In all
leg muscles tested, except the GAS muscle, TAM caused
an accumulation of the type I ﬁbers (fatigue-resistant,ajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Effects of TAM treatment on the mechanical properties of the triceps muscle. Isometric force characteristics were determined on male dystrophic
mice (Dys), male dystrophic mice treated with 10 mg/kg per day of tamoxifen for 15 months (TAM), male wild-type mice (wt), and female dystrophic mice
(FEM). A: Phasic twitch traces normalized for muscle cross section showing that TAM-treated triceps developed much higher force than the other groups.
B: Phasic twitch traces normalized to their maximum peak value, highlighting the slower kinetics of contraction and relaxation of TAM-treated triceps.
C: Tetanic tensions normalized for muscle cross section showing that TAM-treated triceps were as strong as normal ones. D: Curves connecting the frequency of
stimulation to muscle tension output, showing the slower contractile phenotype of the TAM-treated triceps. E: Loss of muscle tension on repeated tetanic
contractions, showing that TAM made the triceps more resistant to fatigue. F: Average force drop calculated from the curves in E, showing that TAM prevented
contraction-induced loss of force. The values represent means  SEMs of 8 to 11 mice. *P  0.05, **P  0.01, and ***P  0.001 compared with the Dys
group; yP  0.05, yyP  0.01, and yyyP  0.001 compared with the TAM group.
Tamoxifen Ameliorates Muscular Dystrophyslow-contracting ﬁbers) or type IIA ﬁbers (fatigue-resistant,
fast-contracting ﬁbers), with a concomitant reduction in the
type IIX and IIB ﬁbers (fatigue-sensitive, fast-contracting
ﬁbers). By contrast, the DIA showed an opposite response
to TAM. As a result of these ﬁber type shifts, the ratio of
types (I þ IIA) to IIB ﬁbers was normalized in the EDL, the
soleus, the TA, and the DIA muscles of TAM-treated mice
(Supplemental Figure S4, FeJ).
Effects of TAM Treatment on the Expression of Muscle
Markers
Proteins from GAS muscle extracts were analyzed by We-
stern blot analysis. Their levels were corrected for MyHC
content and normalized to the levels in the Dys group
(Figure 6). Compared with the wt mice, the GAS muscle
of the Dys mice contained signiﬁcantly more utrophin,
calsequestrin 2, SERCA2, and calcineurin but less calse-
questrin 1. Treatment of Dys mice for 15 months with TAM
signiﬁcantly enhanced the expression of utrophin (þ27%),
a7 integrin (þ36%), aB-crystallin (þ61%), calsequestrin 2The American Journal of Pathology - ajp.amjpathol.org(þ39%), and calcineurin (þ38%) and reduced the levels of
parvalbumin (35%), calsequestrin 1 (28%), SERCA1
(25%), and SERCA2 (18%) (Figure 6, AeJ).
Effects of TAM Treatment on Expression of ERs
The expression levels of ERa and ERb were explored in the
GAS muscle. RT-qPCR showed that ERa mRNA levels
were similar in all groups (Figure 7A). In contrast, total ERb
mRNA levels were 2.3 times more abundant in the Dys
mice than in the wt mice. These levels were further
increased (þ40%) by TAM treatment, resulting in ERb
mRNAs being 3.2 times higher than in the wt mice
(Figure 7B). As shown by nested PCR with the use of
primers ﬂanking exon 7 (Figure 7C), the levels of ERb1
mRNA, encoding the physiologically active ERb subtype,
were unchanged on TAM treatment. We found that the
increase in ERb mRNAs was mostly caused by the accu-
mulation of the mRNA encoding ERb2, a variant having
an extended ligand-binding domain with lower afﬁnity
for estrogens (Figure 7D).28,39 The ERb2/ERb1 mRNA493
Figure 4 Effects of TAM treatment on diaphragmmorphology.A: H&E-stained diaphragms frommale dystrophic mice (Dys), male dystrophic mice treated with 10
mg/kg day of tamoxifen for 15 months (TAM), male wild-type mice (wt), and female dystrophic mice (FEM) (left to right). Scale barZ 200 mm. B: Fluorescent wheat
germ agglutinin-stained diaphragms of the same groups as inA. Themicrophotograph of the FEM groupwas omitted. C: The surfaces occupied by myoﬁbers (dark gray
columns), connective tissue (light gray columns), andadipose tissue (white columns)wereexpressed as thepercentage of the total diaphragmcross-sectional area. The
relativeweight (D), thickness (E),ﬁber number (F), andﬁber layers (G) of thediaphragmswere increasedby TAM treatment.H: The number ofﬁber layers permillimeter
was not changed by TAM, but an increase of centronucleatedmyoﬁbers (I) andmeanﬁber diameter (J) was noted. For clarity, the scatter plots in J show thediameter of
500 individual ﬁbers per group of>6000 ﬁbers analyzed. The statistical analyses were performed on the total ﬁber populations. The values in CeI represent themeans
 SEMs of 8 to 11 mice. *P  0.05, **P  0.01, and ***P  0.001 compared with the Dys group; yP  0.05, yyyP  0.001 compared with the TAM group.
Dorchies et al
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Figure 5 Effect of TAM treatment on heart ﬁbrosis. Hearts were ﬁxed in 4%
buffered paraformaldehyde. After inclusion in parafﬁn sections (5 mm thick)
across the ventricles were stained with Masson trichrome. The ﬁbrotic deposits
appear as a blue staining on a red background. A: Representative heart sections
from amale dystrophic mouse (Dys) (top left), a male dystrophic mouse treated
with 10 mg/kg per day of tamoxifen for 15 months (TAM) (top right), a female
dystrophic mouse (FEM) (bottom right), and a male wild-type mouse (wt)
(bottom left). B: Higher magniﬁcation view of the marked area in A, showing
the ﬁbrotic scars stained in blue. C: The areas stained blue were quantiﬁed and
expressed as the percentage of the total tissue surface. Sections collected 1.50
mm, 2.25 mm, and 3.00 mm from the apex were analyzed and the values were
averaged for every mouse. The values represent means SEMs of 8 to 11 mice.
Scale bars: 2mm (A); 400mm (B). **P 0.01, ***P 0.001 compared with the
Dys group; yP  0.05, yyyP  0.001 compared with the TAM group.
Tamoxifen Ameliorates Muscular Dystrophy
The American Journal of Pathology - ajp.amjpathol.orgratio was seven times lower in Dys mice than in wt mice
(Figure 7E). TAM treatment elevated the ERb2/ERb1 ratio
more than fourfold, bringing it close to that of wt mice
(Figure 7E). The mRNAs encoding shorter ERb variants
(ERb5, ERb5A, and ERb6), which are expressed in the
ovaries, were not detected in the GAS muscles from any
group (Figure 7F). Western blot analysis showed that ERa
and ERb1 proteins were, respectively, 4.3 times and 3.5
times more abundant in Dys muscles than in wt muscles
(Figure 7, G and H), whereas ERb2 was expressed at similar
levels in both groups (Figure 7I). TAM did not modify
ERa and ERb1 protein expression but caused a fourfold
accumulation of the ERb2 isoform in dystrophic muscle
(Figure 7I), resulting in complete normalization of the
relative ERb2/ERb1 protein ratio (Figure 7J).
Levels of TAM and Its Metabolites in Plasma and
Muscle
We determined the concentrations of the E and Z isomers of
TAM and of three major TAM metabolites in the plasma and
in the GAS muscle of the TAM group. Results and repre-
sentative chromatographic proﬁles are shown in Table 4 and
Supplemental Figures S5 and S6, respectively. TAM is-
omers were the major species, followed by 4-OH-TAM,
4-hydroxy-N-desmethyl-TAM (also known as endoxifen),
and N-desmethyl-TAM isomers. The latter were below the
limit of quantiﬁcation of the assay for the plasma. The
compounds were 9 to 20 times more abundant in the GAS
muscle than in the plasma. The levels of TAM and its
metabolites in the muscle and the plasma of the TAM-treated
mice were in the low nanomolar range. Unexpectedly, these
levels were up to two to three orders of magnitude lower than
those found in the same tissues of patients with breast cancer
under standard TAM treatment41,42 or of normal mice and
rats.43 In addition, in our TAM-treated mice, the E and Z
isomers were present in roughly similar quantities, which
contrasts with humans treated for breast cancer whereby the
E isomers are usually only present in trace amounts.37,44 Of
note, we analyzed the food pellets and ruled out a Z-to-E
interconversion during the preparation and the storage of the
modiﬁed chow.Discussion
TAM, a ﬁrst-generation SERM, administrated orally for 15
months at 10 mg/kg/day to mdx5Cv mice caused remark-
able muscular improvements: i) the ability of the mice to
maintain their grip was increased, suggesting that the
body musculature was able to develop more force; ii) the
triceps surae, a large group of muscles in the leg, displayed
a striking enhancement of contractile features; iii) the DIA,
the most severely affected muscle in dystrophic mice, became
bigger, contained more ﬁbers, but less ﬁbrotic deposits; and
iv) the heart showed a signiﬁcant reduction in the extent of495
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Figure 6 Effects of TAM treatment on the expression of muscle markers. Western blot analyses were performed on gastrocnemius extracts prepared from
male dystrophic mice (Dys), male dystrophic mice treated with 10 mg/kg per day of tamoxifen for 15 months (TAM), and male wild-type mice (wt). AeJ: The
myosin heavy chains (A), shown by Coomassie Blue staining, were used for correcting the signals of the following muscle markers: utrophin (B), a7 integrin
(C), aB-crystallin (D), parvalbumin (E), calsequestrin 1 (F), calsequestrin 2 (G), SERCA1 (H), SERCA2 (I), and calcineurin (J). The position of the molecular
weight markers is indicated (in kDa). The values were normalized to the average value of the Dys group and represent the means  SEMs of 11 mice per group.
*P  0.05, **P  0.01, and ***P  0.001 compared with the Dys group; yyyP  0.001 compared with the TAM group.
Dorchies et alﬁbrosis. To the best of our knowledge, this is the ﬁrst report
on the use of TAM on a model of muscular dystrophy.
Rationale for Using TAM
TAM and its active metabolites have been intensively
studied for their ability to control survival, growth, and
other functions of estrogen-dependent cell populations in
the mammary glands, uterus, ovaries, and bones.17e19,45
Apart from these effects, other actions, including preven-
tion of oxidative stress,20 protection against contraction-
induced membrane damage,14 modulation of calcium
handling,24e26 prevention of mitochondria-mediated cell
death,46 and inhibition of ﬁbrosis22,23,47 have been docu-
mented for TAM and its metabolites. These processes
contribute to the pathogenic mechanisms at work in
dystrophic muscle, and targeted interventions have been
shown to improve the phenotype of dystrophic muscle to
some extent.7,31,33,35,48e51 Therefore, we reasoned that
TAM should ameliorate the structure and the function
of dystrophic muscles in mice. The ﬁndings described in the
present report show that TAM remarkably ameliorated
the function and the structure of murine dystrophic muscles.
All of the effects reported in the present study were ob-
tained with tissue levels of TAM and its major metabolites
much lower than those reported in prior studies on normal496rodents.43,52 In addition, we found that the E isomers
accounted for an important part of the total TAM and
metabolites. In humans, the unusual occurrence of high
levels of the E isomers has been correlated with breast
cancer resistance to TAM therapy and speciﬁc proﬁles of
TAM-metabolizing cytochrome P450 enzymes.53 More
work is needed to clarify why the dystrophic mice display
lower levels of TAM and its metabolites compared with
normal mice43 and high amounts of E isomers compared
with humans.37,44
TAM Tolerability
As judged by the relative weight of selected organs and
overall behavior, long-term administration of TAM to
dystrophic mice was well tolerated. TAM signiﬁcantly di-
minished the weight gain of the treated mice, which is likely
because of the reduction of white fat. At the end of the
treatment period, the TAM-treated males weighed the same
as age-matched females.
Protective Actions of TAM on Muscle Function and
Supporting Molecular Findings
Using several techniques, we have demonstrated that TAM
ameliorates various force parameters of dystrophic muscle.ajp.amjpathol.org - The American Journal of Pathology
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Figure 7 Effects of TAM treatment on the expression of estrogen receptors. Total protein and mRNA extracts were prepared from gastrocnemius
muscles of male dystrophic mice (Dys), male dystrophic mice treated with 10 mg/kg per day of tamoxifen for 15 months (TAM), and male wild-type mice
(wt). Brain (Bra) and ovary (Ova) extracts were included for comparison. The levels of ERa (A) and ERb (B) mRNAs were determined by real-time qPCR.
CeE: The relative abundance of the ERb1 and ERb2 isoforms were evaluated after nested PCR, followed by gel electrophoresis and densitometric analysis
of the bands. C: Representative agarose gel, showing PCR ampliﬁcation of the ERb1 and ERb2 isoforms. The molecular weight markers are shown (base
pairs). D: Relative abundance of the ERb1 and ERb2 isoforms, normalized to the total ERb content in the Dys group. E: ERb2-to-ERb1 mRNA ratio. F:
Denaturing urea-polyacrylamide gel electrophoresis showed that gastrocnemius muscles did not express small ERb isoforms (ERb5, ERb5A, ERb6) that can
be found in ovaries (arrows). The molecular weight markers are shown (bases). Western blot quantiﬁcation of ERa (G), ERb1 (H), and ERb2 (I). The
position of the molecular weight markers is indicated (in kDa). J: ERb2-to-ERb1 protein ratio normalized to the values of the Dys group. The data
represent the means  SEMs of 11 mice per group. *P  0.05, **P  0.01, and ***P  0.001 compared with the Dys group; yyP  0.01, yyyP  0.001
compared with the TAM group.
Tamoxifen Ameliorates Muscular DystrophyThe wire test, like other hanging tests, is a rather stringent
assay that challenges many muscles simultaneously, in-
cluding those of the limbs as well as the trunk, abdominal,
and back muscles.40 The much-increased score at the wire
test showed that TAM greatly improved overall muscle
function of active dystrophic mice. This score could be
affected by changes in force, fatigability, and possibly also
balance. Therefore, we extended the evaluation of muscle
function with the use in situ isometric contractions of the
triceps surae, a large muscle group of the lower leg that is
representative of most locomotor muscles. In agreement
with the grid test ﬁndings, we found that the Pt and the Po
developed per unit of muscle cross section were much higher
in the TAM-treated triceps than in triceps from untreated
dystrophicmice. In addition, and as shown by longer TTP and
RT1/2 and smallermaximum rates of tension development andThe American Journal of Pathology - ajp.amjpathol.orgtension loss, TAM conferred much slower contraction
kinetics to the triceps surae. The resistance of muscle to
repeated tetanic contractions was also much higher in TAM-
treated mice than in wt mice.
It has been established by others that the transient estrogen
rise during the menstrual cycle correlates with enhanced
muscle force,12 and in certain paradigms estrogens conferred
slower contraction and relaxation rates to the muscles,12,54
involving either an alteration in calcium handling54 or
a decrease in type IIB ﬁbers.55
TAM made dystrophic muscles even stronger than wt
muscles, which one may ﬁnd surprising. By contrast to what
is expected with strategies aimed at re-introducing the
missing dystrophin,8 the mechanisms of action of active
pharmacologic compounds do not necessarily involve the
restoration of impaired signaling pathways and homeostatic497
Table 4 Levels of TAM and its metabolites in plasma and gastrocnemius muscle
Compounds
Plasma Gastrocnemius
ng/mL nmol/L ng/g nmol/L
(Z)-tamoxifen 1.25  0.30 3.35  0.80 20.18  4.58 54.32  12.32
(E)-tamoxifen 1.75  0.14 4.71  0.38 16.01  1.87 43.11  5.02
(Z)-4-hydroxytamoxifen 1.22  0.37 3.14  0.97 13.31  4.11 34.35  10.60
(E)-4-hydroxytamoxifen 1.39  0.11 3.59  0.28 14.81  2.06 38.23  5.30
(Z)-N-desmethyl-tamoxifen 0.13  0.03 0.37  0.09 2.49  0.50 6.96  1.40
(E)-N-desmethyl-tamoxifen 0.30  0.04 0.84  0.10 3.69  0.42 10.31  1.16
(Z)-endoxifen 0.29  0.05 0.78  0.13 5.04  0.83 13.49  2.21
(E)-endoxifen 0.19  0.02 0.51  0.06 3.82  0.49 10.22  1.32
Values represent mean  SEM of either 8 plasma or 11 muscles from TAM-treated mice. The plasma values for (Z) and (E)-N-desmethyl-tamoxifen are below
the limit of quantiﬁcation of the method and are shown for reference only.
Dorchies et albalances back to normal levels. Moreover, it should be
noted that the force developed by unexercised normal
muscle does not represent an absolute upper limit that can in
no condition be reached or exceeded. Instead, the force of
normal muscles can be augmented by several conditions,
including the use of doping substances and exercise that
causes muscles to display an optimal redox balance and to
ensure adaptation to the novel energy demand and structural
requirements.56e59 We suggest that TAM may have trig-
gered and enhanced alternative pathways and compensatory
mechanisms that could collectively ameliorate dystrophic
muscle function and force output, possibly to levels above
those of wt muscle.
Our ﬁndings of a slower rate of contraction and an
enhanced resistance to fatigue in muscles from TAM-treated
mice are of signiﬁcance for the pathophysiology of muscular
dystrophy. We established that the slower twitches re-
sulted from a fast-to-slow ﬁber type shift and were accom-
panied by a molecular signature typical of slow-contracting
muscles:
First, the slow-twitch phenotype is partly governed by the
protein phosphatase calcineurin.60 Our ﬁnding that TAM
enhanced calcineurin expression in the GAS muscle suggests
a fast-to-slow phenotype transition. This is in agreement
with data showing that chronic activation of calcineurin in
normal skeletal muscle promoted fast-to-slow ﬁber transi-
tion, increased endurance, improved resistance to fatigue,
and enhanced mitochondrial oxidative function.61,62 In
support of a protective role for calcineurin in dystrophic
muscle, reports indicate that inhibition of calcineurin activity
by cyclosporin A aggravated the mdx phenotype, whereas
constitutively active calcineurin protected mdx muscles from
damage.63
Second, it is established that the fast-contracting type IIB
ﬁbers of both patients with DMD and mdx mice are more
susceptible to damage than the slow-twitch type I ﬁbers.64,65
This might be because of higher antioxidant defense
mechanisms and accumulation of utrophin, a dystrophin
homologue, in slow compared with fast ﬁbers.66 The EDL,
TA, and soleus muscles of the TAM-treated mice contained
an increased number of type I ﬁbers or of fast-twitch,498fatigue-resistant type IIA ﬁbers and, consequently, dis-
played an increased value of the (I þ IIA)/IIB ﬁber ratio,
which was restored to normal. This index was also nor-
malized in the DIA, although this was achieved through
a relative reduction of the type I and IIA ﬁbers, which might
result from a protection of the fragile type IIB ﬁbers in that
muscle.
Third, ﬁber type shift did not occur in the GAS muscle
because the (I þ IIA)/IIB ﬁber index was similar in all
groups, which is in agreement with studies by others
showing similar ﬁber type compositions in normal and
dystrophic GAS muscle.67 However, Western blot analyses
showed changes in the levels of calcium handling proteins,
again suggestive of a transition toward a slower phenotype.
The GAS muscle from TAM-treated mice contained more
of the slow typeespeciﬁc protein calsequestrin-2 together
with reduced levels of the fast typeespeciﬁc proteins
SERCA1, calsequestrin-1, and parvalbumin (reviewed in
Berchtold et al68 and Reggiani and Kronnie69). SERCA2
levels in dystrophic GAS muscle were also reduced by
TAM close to normal amounts. Interestingly, SERCA2 was
found to be overexpressed in the fast-twitch EDL muscle in
mdx mice, likely as a compensatory mechanism.70 We
suggest that the TAM-induced reduction of SERCA2 in
GAS muscle might result from an alleviation of the dystr-
ophic symptoms.
We have also established that TAM treatment enhanced
the accumulation of several structural proteins, such as the
dystrophin homologue utrophin, a7 integrin, and aB-
crystallin. When overexpressed in mdx mice, utrophin and
a7 integrin have proven to be of therapeutic interest by
acting as surrogates for the missing dystrophin.32,71,72 aB-
crystallin is a small heat shock protein that is much more
abundant in slow-twitch than in fast-twitch muscles.73 It acts
as a chaperone for several myoﬁbrillar proteins such as
desmin, a muscle-speciﬁc intermediate ﬁlament that is crit-
ical for maintaining the integrity of the myoﬁlaments, and
for ensuring their proper anchoring to other binding
partners.73 Of note, mutations in either desmin or aB-
crystallin result in a variety of muscular disorders.74 In
support of a protective role for TAM-induced accumulationajp.amjpathol.org - The American Journal of Pathology
Tamoxifen Ameliorates Muscular Dystrophyof structural proteins, recent studies reported that up to 20%of
the force deﬁcit in oldmdxmice is due to altered myoﬁlament
architecture75 and that reciprocally damaging contractions
impair myoﬁlament activity.76 Taken individually, the over-
expression level of every one of these structural proteins is
likely too low to promote signiﬁcant protection. We suggest
that their simultaneous overexpression contributed to the
TAM-induced increase of muscle force and to the recovery of
membrane stability.
Altogether, the ﬁber type shifts, the increased levels of
calcineurin, the accumulation of various structural proteins,
and the alterations in calcium handling proteins suggest that
TAM triggered complex transcriptional programs that pro-
tected the muscle, at least partly, via the acquisition of
a slower and fatigue-resistant phenotype.60,62
Protective Actions of TAM on Overall Muscle Structure
Most muscles of the mdx5Cv mouse undergo massive
necrosis atw3 to 5 weeks of age, followed by the formation
of new myoﬁbers retaining internal nuclei and displaying an
important scattering of their diameter. From 8 to 10 weeks
of age, the degeneration-regeneration cycles continue at
a lower rate, and at w1 year of age, as the self-repair
capabilities of the muscle decline, connective tissue inﬁl-
tration becomes prominent. In young dystrophic mice,
centronucleated ﬁbers are a reliable marker of the proportion
of ﬁbers that have disappeared due to prior necrosis.31,34,51
In the present study, the interpretation of centronucleation is
complicated by the long duration of treatment, during which
the muscles likely underwent several cycles of necrosis-
regeneration, and by the fact that the regenerated ﬁbers
are more vulnerable than the original ones.77 However, it is
likely that the decreased centronucleation in the soleus and
the TA muscles is subsequent to prevention of necrosis and
that the increased proportion of regenerated ﬁbers in the
EDL muscle and the DIA results from enhanced regenera-
tion. This view is strongly supported by the relative weights
of these muscles, the alteration of which parallels the cen-
tronucleation index. Whether these muscle-speciﬁc effects
correlate with different expression proﬁles of the ERs and/or
their nuclear cofactors in different muscles remains to
be established. This possibility ﬁnds some support from
earlier work to suggest higher ER levels in slow-twitch
muscles from rabbit78 as well as from recent ﬁndings from
Feder et al79 who found altered ER expression in EDL
and quadriceps muscles of mdx mice (D. Feder, personal
communication).
Normalization of myoﬁber size, reduction of the
scattering of myoﬁber diameter, and decreased ﬁbrosis
are considered positive outcomes in the evaluation of
therapeutic interventions in older dystrophic mice. Overall,
several muscles from both the anterior and the posterior
lower leg as well as the DIA showed a favorable evolution
of one or more of these parameters with TAM. We believe
that most of the musculature beneﬁted similarly from TAMThe American Journal of Pathology - ajp.amjpathol.orgexposure, which is supported by the enhanced performance
at the wire test.
Protective Actions of TAM on Diaphragm and Heart
TAM has been shown to prevent ﬁbroblast activation,
decrease collagen synthesis, and inhibit the release of
transforming growth factor (TGF)-b, a major proﬁbrotic
mediator, in several conditions such as keloids, rhinophyma,
Dupuytren disease, and retroperitoneal ﬁbrosis.22,23,47,80
Here, we demonstrate that TAM decreased the progression
of ﬁbrosis in the dystrophic heart and DIA. Furthermore,
TAM showed additional protective effects on the DIA. It
ameliorated the myoﬁber diameter, increased the proportion
of regenerated ﬁbers, and greatly enhanced the thickness of
the muscle, which resulted mostly from an increase in the
total number of myoﬁbers. After TAM treatment, the net
amount of tissue consisting of myoﬁbers likely to contri-
bute to the respiratory function was augmented by 72%.
Collectively, these results suggest that TAM alleviated the
muscular dystrophy in the DIA and strongly promoted the
formation of new myoﬁbers. In support of this, we found
that the plasma level of TGF-b, a growth factor that controls
muscle regeneration and ﬁbrosis, was reduced (unpublished
data). The DIA is the muscle of the dystrophic mouse that
best mirrors the human condition.81 Several pharmacologic
interventions, such as immunosuppressors, green tea po-
lyphenols, and blockers of TGF-b signaling pathways,
reduced ﬁbrosis in the DIA.51,82,83 Other substances (re-
viewed in Judge et al5), such as halofuginone and deﬂaza-
cort (but not prednisolone), were found efﬁcacious for
ameliorating cardiac function or reducing cardiac ﬁbrosis.
Together with losartan,50 TAM appears to be one of the few
compounds that reduces the development of ﬁbrotic scars in
both the DIA and the heart of dystrophic mice. This may be
related to their common ability to reduce TGF-b. Improving
respiratory and cardiac functions is a challenging issue for
ameliorating the quality of life and increasing the life
expectancy of patients with DMD.4,5 This makes TAM
particularly attractive as a therapeutic agent for treating
muscular dystrophy.
Signiﬁcance of ER Expression and Low Levels of TAM
and Metabolites in Muscle
Natural estrogens and TAM are lipophilic compounds that
accumulate in biological membranes, where they are th-
ought to exert a variety of actions that involve neither ER
nor transcription. In in vitro systems, short-term exposure to
high concentrations of TAM were found to increase
membrane ﬂuidity,84 to protect phospholipids from perox-
idation20 and to directly modulate the activity of ion chan-
nels and pumps.24e26 Typically, these effects were seen
with 1 to 20 mmol/L TAM in the extracellular ﬂuid, which
likely leads to much higher local concentrations in the
membranes of the cultured cells. Several pharmacodynamic499
Dorchies et alstudies on normal mice and rats reported that TAM and its
metabolites reach concentrations in the low micromolar
range in various tissues, including skeletal muscle.43,52 Our
ﬁndings show that the total concentration of TAM and its
metabolites in the GAS muscle of dystrophic mice was
w200 nmol/L, which is likely insufﬁcient for triggering
physical actions on the membrane. Moreover, data from
others suggest that direct membrane actions of TAM would
not prevail in vivo. Koot and colleagues14 reported that
TAM-induced protection of rat skeletal muscles from da-
maging contractions was achieved after long-term treatment,
whereas short-term (24 hours) treatment was ineffective.
Therefore, we believe that the decreased CK value that we
report here is the consequence of ER-dependent mecha-
nisms that lead to myoﬁber stabilization rather than a direct
effect on membrane ﬂuidity or stability. In fact, we have
recently demonstrated that doses of TAM as low as 0.1 mg/
kg/day (ie, 100 times lower than the dose used in the present
study) still produced signiﬁcant improvements of most
motor endpoints, lowered plasma CK levels, and reduced
the number of Evans blue dye-permeable ﬁbers and that
TAM actions were antagonized by the ER blocker fulves-
trant (O.M. Dorchies et al, manuscript in preparation),
which provides strong support for receptor-mediated effects
of TAM on dystrophic muscle.
Most of the effects of estrogens, TAM, and TAM me-
tabolites result from their high-afﬁnity binding to ERa and
ERb that are expressed in estrogen-responsive tissues of
both males and females, including skeletal muscle.10,11,28
Several ERb isoforms exist. ERb1 is considered as the
physiologically active isoform, whereas ERb2, a longer
isoform with much reduced afﬁnity for estrogens, would act
in a dominant negative manner for the other ERs.27,28 We
report here, for the ﬁrst time, that dystrophic muscle is
enriched in both ERa and ERb. This could well be the
underlying reason for the unexpectedly high responsiveness
of this tissue to TAM. Moreover, we found that the imbal-
ance in the relative amounts of ERb1 and ERb2 tended to be
normalized by TAM due to increased expression of ERb2.
This is particularly interesting in light of recent studies that
demonstrate a role for ERb in preventing both hypertrophy
and ﬁbrosis of the heart,85,86 although these studies do not
allow distinguishing the roles of different ERb isoforms.
Previous work by others have suggested that ER are
expressed in various cell types within mammalian skeletal
muscle, including endothelium, myoblasts, and myo-
ﬁbers.10,11 In our hands, immunoﬂuorescence labeling of
mouse muscle tissues with the use of a large number of
commercially available antibodies produced inconsistent
staining patterns (data not shown). Consequently, more
work is needed to unequivocally identify the cell type(s) that
convey the increased ER expression in dystrophic skeletal
muscles.
After binding their ligands, homodimers or heterodimers of
ERa/ERb regulate the transcription of target genes that bear
palindromic estrogen-response elements in their promoter500regions.87 We have screened for the presence of estrogen-
response elements in the upstream regions of the genes
encoding several of the proteinswhose expressionwas altered
by TAM treatment. Although no complete estrogen-response
element was found, these regions bear many estrogen-
response element half-sites, which, in certain instances, may
sufﬁce to control the expression of estrogen target genes.87
More experiments are needed to establish if TAM stimu-
lated the expression of these proteins through increased
transcription.
Tissue-speciﬁc estrogen sensitivity and response to TAM
are essentially deﬁned by the pattern of expression of ERa,
ERb, co-activators, and co-repressors. On binding to ERa or
ERb, TAM alters the set of co-regulators that are recruited,
resulting in either proestrogenic or antiestrogenic effects in
a tissue-speciﬁc manner.28 Several of our ﬁndings suggest
that TAM mimics estrogens on skeletal muscle. TAM
increased the force and the resistance to fatigue and slowed
the kinetics of contraction. Moreover, TAM-treated males
weighed the same as age-matched females, most muscles
from both groups had similar relative weights, and their
plasma CK levels were similarly low. However, major
differences remained between TAM-treated males and
untreated females. As judged by the physical impulse scores
determined from the wire hanging test and by the phasic and
tetanic forces, the females were as weak as the untreated
males, the female DIA accumulated much more adipose
tissue, and both the female DIA and heart were not protected
against ﬁbrosis. Therefore, although our results indicate that
TAM exerted protective effects on the overall musculature,
this compound does not just “feminize” skeletal muscles of
dystrophic mice nor does it fully mimic the natural estrogens.
In fact, TAM binding to ER results in either proestrogenic or
antiestrogenic actions, depending on the cell type,19 which is
characteristic of many SERMs, whereas natural estrogens
elicit proestrogenic responses only. In addition, TAM and
natural estrogens maymodulate ER-independent pathways in
a different manner,24e26,88 resulting in distinct biological
responses. Of note, it is likely that the levels of circulating
estrogens were reduced in the relatively old females used in
this study.
The issue of whether TAM is proestrogenic or antiest-
rogenic for dystrophic muscle is currently under investiga-
tion in our laboratory. This is complicated by the fact that
several TAM metabolites exhibit a 30- to 100-fold higher
afﬁnity for ERs and display a stronger antiestrogenic
activity than the parental drug and that the (E)-isomers
display much lower antiestrogenic activity than the (Z)-
isomers, at least as evaluated on breast cancer cells.89 The
use of other SERMs, such as raloxifene, whose biological
activity does not depend on metabolites, might be useful for
clarifying the roles of estrogen signaling in dystrophic
muscle function. However, current work in our laboratory
shows that raloxifene is much less efﬁcacious than TAM
on mdx5Cv mice (O.M. Dorchies et al, manuscript in
preparation).ajp.amjpathol.org - The American Journal of Pathology
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Over the past years, considerable efforts have been made
toward therapies that replace or repair the defective
dystrophin gene and permit the production of quasi-
dystrophin.8 However, technologic, cost, and safety issues
obstruct the development of these approaches. In our view,
the evaluation of known orally active small-molecular weight
compounds with well-characterized pharmacodynamic and
safety proﬁles presents signiﬁcant advantages over other
therapeutic avenues.7 In particular, theymight provide beneﬁt
to patients with DMD within a minimum period of time and
are much less costly.
Our study suggests that TAM might be well-suited
for this purpose. Besides its good safety proﬁle in
adults,17e19,90 several studies report that it was also well
tolerated when given for up to 48 months to 13-to 16-year-
old prepubertal boys and for 12 months to girls as young as
3 years.45,91,92 Importantly, in these studies, TAM did not
alter the acquisition of male sexual traits. However, no data
exist about the safety of TAM on growing boys as young as
5 to 7 years of age, at the time when the disease is diagnosed
and treatment is likely to be initiated. This limitation should
be taken into account if TAM is being evaluated on young
patients with DMD.
Patients with DMD under usual steroid medications
exhibit reduced growth and altered bone quality, which
correlates with more frequent fractures. However, the
reduction of the stature might participate in the therapeutic
beneﬁts of steroids (see Bianchi et al93 and references
within). By contrast, TAM prevents bone loss17,94 and has
been shown to increase the height of short boys by
decreasing the rate of bone maturation.92 At present, it is not
known whether the foreseen action of TAM on stature might
be a therapeutic issue for boy with DMD.
Our study shows that very low levels of TAM and TAM
metabolites are sufﬁcient to cause major therapeutic effects
on the dystrophic mouse, which is encouraging in the
perspective of a clinical application of our ﬁndings to
patients with DMD. It is possible that therapeutic TAM
concentrations might be reached with lower than standard
TAM regimen, the safety of which has been established for
more than 20 years. The speciﬁc beneﬁts elicited by the E
isomers of TAM metabolites, which were produced in
substantial amounts in the dystrophic mice but are barely
detected in humans,37,44 deserve further examination. This
could result in lower than expected beneﬁts when extrapo-
lating our results from mice to patients with DMD.
In conclusion, our preclinical evaluation of TAM in
a mouse model of DMD showed promising improvements
of skeletal and cardiac muscles. However, more investiga-
tions are required to establish the actions of TAM on further
aspects of the dystrophic disease, such as the prevention of
the initial muscle necrosis and the modulation of the
inﬂammatory responses. Our further work will also aim at
elucidating the molecular mechanisms that underlie theThe American Journal of Pathology - ajp.amjpathol.orgactions of TAM on dystrophic skeletal muscle, in particular
with respect to the signaling pathways, the contributions of
the ERs, and the speciﬁc activities of TAM metabolites.Acknowledgments
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